Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
DMBT1 Double Nickase Plasmid (h): sc-402615-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- DMBT1 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- DMBT1 Double Nickase Plasmid (h) and DMBT1 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting DMBT1. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: DMBT1 Antibody (G-4): sc-514566
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
DMBT1 Double Nickase Plasmid (h) | sc-402615-NIC | 20 µg | $410.00 | |||
DMBT1 Double Nickase Plasmid (h2) | sc-402615-NIC-2 | 20 µg | $410.00 |
DMBT1 (deleted in malignant brain tumors 1) encodes a secreted, multidomain scavenger receptor cysteine-rich glycoprotein implicated in epithelial host defense and mucosal homeostasis. The protein participates in pattern recognition, agglutination of microbes, and modulation of inflammatory signaling, with reported roles in epithelial differentiation and barrier-associated processes. DMBT1 expression is regulated in response to tissue injury and immune stimuli and has been linked to pathways involving innate immunity, extracellular matrix interactions, and cell–cell adhesion. Altered DMBT1 expression or genomic loss has been associated with diverse epithelial pathologies and tumor biology, supporting its utility as a research target in inflammation, infection biology, and cancer-related mechanisms.
DMBT1 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the DMBT1 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within DMBT1. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt DMBT1 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of DMBT1-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.